Topical cyclosporine in vernal keratoconjunctivitis

J. H. Bleik, K. F. Tabbara

Research output: Contribution to journalArticle

Abstract

In a placebo-controlled, double-masked clinical trial, the authors evaluated the effects of topical 2% cyclosporine on 20 patients with vernal keratoconjunctivitis (VKC). Nineteen patients were male and one was female. Patients ranged in age from 5 to 19 years (mean, 9.7 years). Symptoms of itching, tearing, photophobia, discharge, and foreign body sensation were evaluated and recorded at weekly intervals for a period of 6 weeks. There was a statistically significant decrease in the conjunctival hyperemia, papillary hypertrophy, punctate keratitis, and Trantas' dots in the group of patients treated with cyclosporine but not in the group treated with placebo. No adverse effects and no detectable levels of cyclosporine were noted in the blood in the cyclosporine-treated group. Cyclosporine appears to be safe and effective for the short-term treatment of VKC.

Original languageEnglish (US)
Pages (from-to)1679-1684
Number of pages6
JournalOphthalmology
Volume98
Issue number11
StatePublished - 1991
Externally publishedYes

Fingerprint

Allergic Conjunctivitis
Cyclosporine
Placebos
Photophobia
Keratitis
Hyperemia
Pruritus
Foreign Bodies
Hypertrophy
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bleik, J. H., & Tabbara, K. F. (1991). Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology, 98(11), 1679-1684.

Topical cyclosporine in vernal keratoconjunctivitis. / Bleik, J. H.; Tabbara, K. F.

In: Ophthalmology, Vol. 98, No. 11, 1991, p. 1679-1684.

Research output: Contribution to journalArticle

Bleik, JH & Tabbara, KF 1991, 'Topical cyclosporine in vernal keratoconjunctivitis', Ophthalmology, vol. 98, no. 11, pp. 1679-1684.
Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology. 1991;98(11):1679-1684.
Bleik, J. H. ; Tabbara, K. F. / Topical cyclosporine in vernal keratoconjunctivitis. In: Ophthalmology. 1991 ; Vol. 98, No. 11. pp. 1679-1684.
@article{d54d5e02c2884b3eb9f4d09bc81a310f,
title = "Topical cyclosporine in vernal keratoconjunctivitis",
abstract = "In a placebo-controlled, double-masked clinical trial, the authors evaluated the effects of topical 2{\%} cyclosporine on 20 patients with vernal keratoconjunctivitis (VKC). Nineteen patients were male and one was female. Patients ranged in age from 5 to 19 years (mean, 9.7 years). Symptoms of itching, tearing, photophobia, discharge, and foreign body sensation were evaluated and recorded at weekly intervals for a period of 6 weeks. There was a statistically significant decrease in the conjunctival hyperemia, papillary hypertrophy, punctate keratitis, and Trantas' dots in the group of patients treated with cyclosporine but not in the group treated with placebo. No adverse effects and no detectable levels of cyclosporine were noted in the blood in the cyclosporine-treated group. Cyclosporine appears to be safe and effective for the short-term treatment of VKC.",
author = "Bleik, {J. H.} and Tabbara, {K. F.}",
year = "1991",
language = "English (US)",
volume = "98",
pages = "1679--1684",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Topical cyclosporine in vernal keratoconjunctivitis

AU - Bleik, J. H.

AU - Tabbara, K. F.

PY - 1991

Y1 - 1991

N2 - In a placebo-controlled, double-masked clinical trial, the authors evaluated the effects of topical 2% cyclosporine on 20 patients with vernal keratoconjunctivitis (VKC). Nineteen patients were male and one was female. Patients ranged in age from 5 to 19 years (mean, 9.7 years). Symptoms of itching, tearing, photophobia, discharge, and foreign body sensation were evaluated and recorded at weekly intervals for a period of 6 weeks. There was a statistically significant decrease in the conjunctival hyperemia, papillary hypertrophy, punctate keratitis, and Trantas' dots in the group of patients treated with cyclosporine but not in the group treated with placebo. No adverse effects and no detectable levels of cyclosporine were noted in the blood in the cyclosporine-treated group. Cyclosporine appears to be safe and effective for the short-term treatment of VKC.

AB - In a placebo-controlled, double-masked clinical trial, the authors evaluated the effects of topical 2% cyclosporine on 20 patients with vernal keratoconjunctivitis (VKC). Nineteen patients were male and one was female. Patients ranged in age from 5 to 19 years (mean, 9.7 years). Symptoms of itching, tearing, photophobia, discharge, and foreign body sensation were evaluated and recorded at weekly intervals for a period of 6 weeks. There was a statistically significant decrease in the conjunctival hyperemia, papillary hypertrophy, punctate keratitis, and Trantas' dots in the group of patients treated with cyclosporine but not in the group treated with placebo. No adverse effects and no detectable levels of cyclosporine were noted in the blood in the cyclosporine-treated group. Cyclosporine appears to be safe and effective for the short-term treatment of VKC.

UR - http://www.scopus.com/inward/record.url?scp=0026096209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026096209&partnerID=8YFLogxK

M3 - Article

C2 - 1800929

AN - SCOPUS:0026096209

VL - 98

SP - 1679

EP - 1684

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -